|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|2116371||1084854||2011||9 صفحه PDF||سفارش دهید||دانلود رایگان|
Osteosarcoma is the most common primary bone tumor in children and adolescents and is typically associated with a poor prognosis. Tumor stem cells (TSCs) are presumed to drive tumor initiation and tumor relapse or metastasis. Hence, the poor prognosis of osteosarcoma likely results from a failure to target the osteosarcoma stem cells. Here, we have utilized three different methods to enrich TSCs in osteosarcoma and further evaluated whether salinomycin could selectively target TSCs in osteosarcoma. Our results indicated that sarcosphere selection, chemotherapy selection and stem cell marker OCT4 or SOX2 over-expression are all effective in the enrichment of TSCs from osteosarcoma cell lines. Further investigation found that salinomycin inhibited osteosarcoma by selectively targeting its stem cells both in vitro and in vivo without severe side effects, and the Wnt/β-catenin signaling pathway may be involved in this inhibition of salinomycin. Taken together, we have identified that salinomycin is an effective inhibitor of osteosarcoma stem cells, supporting the use of salinomycin for elimination of osteosarcoma stem cells and implying a need for further clinical evaluation.
► We have utilized three different methods to enrich TSCs in osteosarcoma.
► Salinomycin could selectively target TSCs in osteosarcoma both in vitro and in vivo.
► Wnt/β-catenin signaling pathway may be involved in this inhibition of salinomycin.
► Salinomycin is an effective inhibitor of osteosarcoma stem cells.
Journal: Cancer Letters - Volume 311, Issue 1, 1 December 2011, Pages 113–121